Spots Global Cancer Trial Database for nsclc
Every month we try and update this database with for nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients | NCT04552613 | Non-small-lung-... NSCLC EGFR Gene Mutat... | EGFR-TKI EGFR-TKI combin... | 18 Years - 80 Years | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy | NCT06317558 | NSCLC | Neoadjuvant imm... Other drugs for... | 18 Years - 85 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer? | NCT06034730 | Lung Cancer | Portable GC dev... | 18 Years - | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | NCT00874848 | NSCLC | Imprime PGG Inj... Cetuximab Paclitaxel Carboplatin | 18 Years - 75 Years | HiberCell, Inc. | |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | NCT04511533 | Metastatic Non ... | Dacomitinib | 18 Years - | Pfizer | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | NCT00975182 | Non-Squamous No... | GDC-0941 erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | NCT03761901 | Carcinoma, Non-... | 1L treatment 2L Treatment 3L treatment | 18 Years - | AstraZeneca | |
| Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens | NCT06252129 | Lung Cancer Lymph Node Meta... Pathologic Proc... | Subjects underg... Control group | 18 Years - | Brigham and Women's Hospital | |
| A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | NCT01268059 | Non-small Cell ... | Carboplatin Paclitaxel MEDI-575 | 18 Years - 99 Years | MedImmune LLC | |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC | NCT05418660 | Non-small Cell ... | Immunotherapy | 18 Years - | University of Milano Bicocca | |
| A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | NCT05571839 | Cutaneous Melan... Non-small Cell ... Colorectal Neop... Pancreatic Neop... Mesothelioma | SGN-BB228 | 18 Years - | Seagen Inc. | |
| A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | NCT01237171 | NSCLC Non Small Cell ... | Cesium-131 Brac... | - | IsoRay Medical, Inc. | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | NCT04383938 | Bladder Cancer Gastric Cancer Non Small Cell ... NSCLC Urothelial Carc... Advanced Solid ... | APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC | NCT00378404 | Non-Small Cell ... | Docetaxel Radiation | 18 Years - | University of Kentucky | |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | NCT00960115 | Non-small Cell ... | Tecemotide (L-B... Single low dose... Placebo Saline | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| T790M Mutation Positive 2nd Line STandard of cAre Registry | NCT02368990 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | NCT02356991 | Non-Small Cell ... | Famitinib Placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network | NCT04564079 | NSCLC | 18 Years - | Exactis Innovation | ||
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | NCT01069328 | Carcinoma, Non-... Lung Cancer | Nexavar (Sorafe... Nexavar (Sorafe... Bevacizumab Bevacizumab Bevacizumab Bevacizumab Paclitaxel Carboplatin | 18 Years - | Bayer | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | NCT06422143 | Non-small Cell ... NSCLC | Pembrolizumab sac-TMT | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT00072618 | NSCLC | Exisulind | 18 Years - | Astellas Pharma Inc | |
| FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | NCT04758949 | Non-Small Cell ... | FL-101 Nivolumab Placebo | 18 Years - | Flame Biosciences | |
| A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | NCT00130728 | Non-Small Cell ... | bevacizumab erlotinib HCl placebo | 18 Years - | Genentech, Inc. | |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | NCT03861156 | Solid Tumor NSCLC EGFR T790M | D-0316 | 18 Years - | InventisBio Co., Ltd | |
| A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer | NCT03427567 | Non-small Cell ... | Sublobar dissec... | 18 Years - | Tongji Hospital | |
| Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT00522938 | Carcinoma, Non-... | CHR-2797 (tosed... erlotinib | 18 Years - | Chroma Therapeutics | |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | NCT05389462 | Advanced Solid ... | ADCT-601 Gemcitabine | 18 Years - | ADC Therapeutics S.A. | |
| A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations | NCT03634059 | NSCLC | Apatinib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | NCT05714891 | NSCLC | JDQ443 | 18 Years - | Canadian Cancer Trials Group | |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | NCT03409458 | Non-Small Cell ... | PT-112 avelumab | 18 Years - | Promontory Therapeutics Inc. | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT | NCT05919641 | Non-small Cell ... Stereotactic Bo... Comprehensive G... | Comprehensive G... | 70 Years - | Odense University Hospital | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | NCT01237171 | NSCLC Non Small Cell ... | Cesium-131 Brac... | - | IsoRay Medical, Inc. | |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | NCT00997334 | Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC) | NCT00879866 | Lung Cancer Non Small Cell ... | EMD 521873 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | NCT03485326 | Non-small Cell ... | - | AstraZeneca | ||
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579 | Non Small Cell ... | Pemetrexed (Ali... Gefitinib (IRES... | 18 Years - 80 Years | Chinese Society of Lung Cancer | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | NCT00866970 | NSCLC Fatigue Cachexia | ALD518 ALD518 ALD518 Infusion of 0.9... | 18 Years - | CSL Behring | |
| MPDL3280A With Chemoradiation for Lung Cancer | NCT02525757 | Lung Cancer Non-Small Cell ... | MPDL3280A Carboplatin Paclitaxel Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. | NCT05326425 | Lung Neoplasms | lazertinib(YH25... | 20 Years - | Seoul St. Mary's Hospital | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer | NCT03808701 | Advanced Squamo... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC | NCT04405661 | NSCLC | 18 Years - 70 Years | Guangzhou Institute of Respiratory Disease | ||
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. | NCT03381066 | Completely Rese... | gefitinib, peme... Vinorelbine, ci... | 20 Years - | Yonsei University | |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer | NCT00098254 | Non-Small-Cell ... | BAY 43-9006 (So... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | NCT04367311 | Lung Cancer NSCLC | Atezolizumab Docetaxel Cisplatin Pemetrexed | 18 Years - | Big Ten Cancer Research Consortium | |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | NCT04507906 | NSCLC Stage IV Checkpoint Inhi... | Nivolumab Combi... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | NCT00492206 | Non Small Cell ... | Cetuximab | 18 Years - | University of Pittsburgh | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | NCT02358473 | Non-Small Cell ... | mogamulizumab Docetaxel | 18 Years - | Kyowa Kirin, Inc. | |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | NCT04720976 | Solid Tumor NSCLC | JAB-3312 Binimetinib Pembrolizumab Sotorasib Osimertinib | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | NCT01186861 | Non-Small Cell ... | OSI-906 erlotinib placebo | 18 Years - | Astellas Pharma Inc | |
| This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | NCT00059722 | Carcinoma, Non-... | ZD6474 Placebo ZD1839 | 18 Years - | Sanofi | |
| Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) | NCT01312337 | Nonsmall Cell L... | salvage iressa | 18 Years - | Samsung Medical Center | |
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | NCT03968419 | Non-small Cell ... | Canakinumab Pembrolizumab | 18 Years - | Novartis | |
| Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) | NCT01511081 | Non-small-cell ... | SBRT (stereotac... SBPT (stereotac... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | NCT00257608 | Non-Small Cell ... | bevacizumab placebo erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | NCT03416231 | NSCLC | Apatinib Docetaxel | 18 Years - | Affiliated Hospital of North Sichuan Medical College | |
| Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma | NCT00903292 | Non-Small Cell ... | erlotinib (Tarc... pemetrexed (Ali... | 20 Years - 80 Years | National Cheng-Kung University Hospital | |
| Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC) | NCT00559611 | Lung Cancer | Endobronchial U... Mediastinoscopy | 18 Years - | M.D. Anderson Cancer Center | |
| Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer | NCT00066885 | Carcinoma, Non-... | calcitriol + do... | 18 Years - | Novacea | |
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | NCT04892472 | Non-small Cell ... | NovoTTF-200T Pembrolizumab (... | 22 Years - | NovoCure Ltd. | |
| Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | NCT03990077 | Nsclc | HL-085 Docetaxel | 18 Years - 70 Years | Shanghai Kechow Pharma, Inc. | |
| BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | NCT00410059 | Lung Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients | NCT03436056 | Metastatic Non-... | Stereotactic Bo... Stereotactic Bo... Stereotactic Bo... Pembrolizumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | NCT03589547 | Stage III Non-s... | Durvalumab SBRT | 18 Years - | Brown University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
